Nycomed

NycomedNycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion.

www.nycomed.com

Nycomed RSS Channel

Display # 
Title Published Date
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 18 January 2012
Nycomed reports double-digit growth across emerging markets in second quarter 2011 17 August 2011
Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets 16 June 2011
Nycomed continues to outperform in emerging markets in first quarter 2011 26 May 2011
Nycomed acquires distribution rights to product portfolio in Turkey 14 April 2011
REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment 31 March 2011
Nycomed well positioned in emerging markets 02 March 2011
Nycomed's novel COPD therapy roflumilast receives FDA approval 01 March 2011
Nycomed to acquire Colombian company Farmacol 06 February 2011
Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines 06 January 2011
Nycomed is keeping the pace in third quarter 2010 10 November 2010
Nycomed to accelerate expansion in China 01 November 2010
Global market launch of Daxas® (Roflumilast) kicks off in Germany 01 September 2010
Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union 07 July 2010
Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® 03 May 2010
Nycomed and Baxter receive FDA approval for TachoSil® 08 April 2010
Nycomed on track in 2009 with strong growth in Key Products 02 March 2010
Nycomed reports continued satisfactory performance in the third quarter 2009 13 November 2009
Nycomed reports sustained momentum in second quarter 2009 20 August 2009
Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD 11 August 2009

Most Popular Now

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Bristol-Myers Squibb and PsiOxus Th…

Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, to...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

FDA approves first and only single …

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) PushtronexTM system (on-body infusor with pref...

Read more

Amgen and Daiichi Sankyo announce a…

Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE 4568) today announced the execution of an exclusive agreement to commercialize nin...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

Boehringer Ingelheim and Lilly anno…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 83...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016